This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $178 in the latest trading session, marking a +1.08% move from the prior day.
Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants
by Zacks Equity Research
Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTV
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
by Zacks Equity Research
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
by Zacks Equity Research
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.
Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHV
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Johnson & Johnson (JNJ) Up 5.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use
by Zacks Equity Research
The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VONV
Should iShares S&P 500 Value ETF (IVE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVE
Should Vanguard S&P 500 Value ETF (VOOV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOOV
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.
Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.
Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MGV